Advertisement

Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy

Abstract

Background. Preclinical studies have shown that several chemotherapeutic agents at low doses may affect the vascular system. Here we report the case of a patient with long-term cancer control by metronomic chemotherapy.
Case presentation. A 62-year-old woman with breast cancer underwent a left mastectomy in July 2007. For a liver metastasis she was given first-line chemotherapy with doxorubicin plus paclitaxel every 21 days. A CT scan after the sixth cycle showed a partial response. It was decided to stop the treatment with doxorubicin and paclitaxel, and start metronomic therapy with cyclophosphamide 50 mg daily orally and methotrexate 2.5 mg twice daily, 2 days a week. After 6 months of this maintenance treatment, CT scan showed a complete response. We examined the expression of vascular endothelial growth factor receptor 2 (VEGFR2) in histological sections of the primary tumor of our patient, finding evidence of overexpression of the receptor. The metronomic treatment is still ongoing, and after 60 months the patient maintains a complete response.
Conclusion. This clinical case highlights how suitable metronomic chemotherapy can be used as maintenance therapy, allowing long-term treatment with no significant toxicity. This case suggests that the level of VEGFR2 is predictive of best response to antiangiogenic therapy.

Tumori 2014; 100(3): e79 - e82

Article Type: CASE REPORT

DOI:10.1700/1578.17238

Authors

Lorenzo Cecconetto, Andrea Casadei Gardini, Elena Tenti, Roberta Maltoni, Sara Bravaccini, Devil Oboldi, Wainer Zoli, Patrizia Serra, Caterina Donati, Samanta Sarti, Dino Amadori, Andrea Rocca

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Cecconetto, Lorenzo [PubMed] [Google Scholar]
    Lorenzo Cecconetto and Andrea Casadei Gardini contributed equally to this work
  • Gardini, Andrea Casadei [PubMed] [Google Scholar]
    Lorenzo Cecconetto and Andrea Casadei Gardini contributed equally to this work
  • Tenti, Elena [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  • Maltoni, Roberta [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  • Bravaccini, Sara [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  • Oboldi, Devil [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  • Zoli, Wainer [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  • Serra, Patrizia [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  • Donati, Caterina [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  • Sarti, Samanta [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  • Amadori, Dino [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  • Rocca, Andrea [PubMed] [Google Scholar]
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.